Conflict between the players in pharmacoeconomic evaluation Richard J MilneTracey Langsdale Newsletter Article 16 February 2013 Pages: 3 - 4
Economic evaluation is important but improvements are imperative Newsletter Article 16 February 2013 Pages: 5 - 5
How should decision makers view cost/QALY league tables? Newsletter Article 16 February 2013 Pages: 6 - 6
Is there a role for ticlopidine in stroke prevention? Newsletter Article 16 February 2013 Pages: 7 - 7
Impact of pharmacist intervention on ceftazidime prescribing Newsletter Article 16 February 2013 Pages: 8 - 8
TCAs or SSRIs for depression? - two different conclusions Newsletter Article 16 February 2013 Pages: 9 - 9
Blood cell reinfusion - ‘promising’ in multiple myeloma Newsletter Article 16 February 2013 Pages: 10 - 10
Impact of surfactant on respiratory distress syndrome Newsletter Article 16 February 2013 Pages: 10 - 11
Patient-controlled or IM analgesia for postoperative pain Newsletter Article 16 February 2013 Pages: 11 - 11
LMWH prophylaxis superior in total hip arthroplasty Newsletter Article 16 February 2013 Pages: 11 - 11
Cefepime or ceftazidime for treating serious infection? Newsletter Article 16 February 2013 Pages: 12 - 12
Identifying essential output measures for cost-utility analysis Newsletter Article 16 February 2013 Pages: 13 - 13
Cost savings from captopril in diabetic nephropathy Newsletter Article 16 February 2013 Pages: 15 - 15